Clinical trials
Phase 4 Adrenal Insufficiency trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Unknown status | 3 |
| Withdrawn | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 1 |
| CAMC Health System | 1 |
| Cardiff University | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Children's Hospital of Eastern Ontario | 1 |
| Hopital La Rabta | 1 |
| Hospices Civils de Lyon | 1 |
| Hospital Universitari Vall d'Hebron Research Institute | 1 |
| Istituto Ortopedico Rizzoli | 1 |
| Johns Hopkins University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adrenal Insufficiency | 23 |
| Giant Cell Arteritis | 2 |
| Hypopituitarism | 2 |
| Polymyalgia Rheumatica | 2 |
| Sepsis | 2 |
| Arthritis, Rheumatoid | 1 |
| Burns | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Eunuchism | 1 |
| Fatigue | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.